-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On December 14th, the pharmaceutical industry reappeared in large-scale mergers and acquisitions.
Australian blood and vaccine giant CSL plans to acquire Swiss pharmaceutical company Vifor Pharma AG for US$11.
7 billion.
Through this acquisition, CSL will obtain a number of Vifor's research and development projects.
The approved product complements the company's existing product pipeline in key areas of treatment, including cardiovascular metabolism, kidney disease, hematology disease and transplantation technology, and makes products more diversified
.
It is reported that after the completion of the acquisition, CSL will have 37 products under development at various stages of development, which is 37% more than CSL's current independent product pipeline, and it is expected to launch as many as 4 products in 2022/23
.
CSL will acquire all publicly held shares of Vifor at a price of US$179.
25 per share
.
This financing is one of the largest transactions in the secondary market in Australia, and it is also a recurring large-scale merger and acquisition event in the global pharmaceutical industry
.
Looking at historical public information, there are not many cases where the value of mergers and acquisitions in the pharmaceutical industry exceeds US$10 billion
.
For example, as early as September 2014, German industry giant Merck announced that it would acquire Aldrich Pharmaceuticals for US$17 billion in order to expand Merck’s life sciences business
.
In December 2018, Japanese pharmaceutical giant Takeda Pharmaceuticals invested US$58 billion to acquire the British pharmaceutical company Shire, aiming to greatly enhance Takeda Pharmaceutical’s position in gastrointestinal diseases, neuroscience and rare diseases, including a type of hemophilia The franchise of drugs
.
In August 2019, the U.
S.
pharmaceutical giant Amgen announced that it agreed to acquire Otezla, a new psoriasis drug under Celgene Pharmaceuticals, for $13.
4 billion.
In January of the same year, Bristol-Myers Squibb announced that it would acquire Celgene Pharmaceuticals for $74 billion.
Strive to meet the needs of patients with cancer, inflammation, immune disease and cardiovascular disease through this acquisition
.
In June 2019, in the face of AbbVie, which is about to expire the patent of "Medicine King" Xiu Mei Le, it announced that the company would acquire Botos manufacturer Allergan at a price of approximately US$63 billion.
The payment method would be cash and equity.
In order to increase the fast-growing treatment business such as medical beauty and eye care
.
On September 30, 2021, Merck announced that it has successfully completed the acquisition of Acceleron Pharma
.
According to the agreement, Merck will acquire Acceleron for US$180 per share in cash, with a total equity value of approximately US$11.
5 billion
.
Acceleron is a clinical-stage biopharmaceutical company focusing on the research and development of anti-cancer drugs and rare drugs for rare diseases
.
On December 9, 2021, Thermo Fisher announced the completion of the acquisition of PPD for US$17.
4 billion
.
The transaction is expected to contribute $1.
50 to Thermo Fisher's adjusted earnings per share in 2022
.
PPD is a company that provides drug development services (CRO) for the biopharmaceutical and biotechnology industries, and has a history of 35 years
.
In fact, not only overseas pharmaceutical companies, but also domestic pharmaceutical companies' mergers and acquisitions continue to occur, but the transaction amount is relatively lower than that of overseas pharmaceutical companies
.
For example, Buchang Pharmaceuticals announced on October 14 this year that the company and its wholly-owned subsidiary Shenzhou Pharmaceuticals intends to acquire 100% of Beijing Chengrui's shares, with a total transaction price of 271 million yuan.
In September, Jiangzhong Pharmaceuticals announced that it intends to transfer equity.
And the acquisition of 51% equity of Hayes Pharmaceuticals by way of capital increase
.
According to incomplete statistics, as of the end of September 2021, there have been more than 100 mergers and acquisitions in China's pharmaceutical industry
.
Since the second half of the year, mergers and acquisitions have remained active, and a large number of companies including Buchang Pharmaceuticals and Yuanda Pharmaceuticals have also issued merger announcements
.
From the industry's perspective, in recent years, pharmaceutical companies have generally faced problems such as revenue growth pressure, patent expiration, and high cost of new drug development.
This has forced large pharmaceutical companies to continuously enrich their product pipelines and stabilize the situation through mergers and acquisitions
.
Some analysts predict that judging from current trends, large pharmaceutical companies may have a large number of mergers and acquisitions in 2022, and the total transaction is expected to exceed 1.
7 trillion US dollars
.
Australian blood and vaccine giant CSL plans to acquire Swiss pharmaceutical company Vifor Pharma AG for US$11.
7 billion.
Through this acquisition, CSL will obtain a number of Vifor's research and development projects.
The approved product complements the company's existing product pipeline in key areas of treatment, including cardiovascular metabolism, kidney disease, hematology disease and transplantation technology, and makes products more diversified
.
It is reported that after the completion of the acquisition, CSL will have 37 products under development at various stages of development, which is 37% more than CSL's current independent product pipeline, and it is expected to launch as many as 4 products in 2022/23
.
CSL will acquire all publicly held shares of Vifor at a price of US$179.
25 per share
.
This financing is one of the largest transactions in the secondary market in Australia, and it is also a recurring large-scale merger and acquisition event in the global pharmaceutical industry
.
Looking at historical public information, there are not many cases where the value of mergers and acquisitions in the pharmaceutical industry exceeds US$10 billion
.
For example, as early as September 2014, German industry giant Merck announced that it would acquire Aldrich Pharmaceuticals for US$17 billion in order to expand Merck’s life sciences business
.
In December 2018, Japanese pharmaceutical giant Takeda Pharmaceuticals invested US$58 billion to acquire the British pharmaceutical company Shire, aiming to greatly enhance Takeda Pharmaceutical’s position in gastrointestinal diseases, neuroscience and rare diseases, including a type of hemophilia The franchise of drugs
.
In August 2019, the U.
S.
pharmaceutical giant Amgen announced that it agreed to acquire Otezla, a new psoriasis drug under Celgene Pharmaceuticals, for $13.
4 billion.
In January of the same year, Bristol-Myers Squibb announced that it would acquire Celgene Pharmaceuticals for $74 billion.
Strive to meet the needs of patients with cancer, inflammation, immune disease and cardiovascular disease through this acquisition
.
In June 2019, in the face of AbbVie, which is about to expire the patent of "Medicine King" Xiu Mei Le, it announced that the company would acquire Botos manufacturer Allergan at a price of approximately US$63 billion.
The payment method would be cash and equity.
In order to increase the fast-growing treatment business such as medical beauty and eye care
.
On September 30, 2021, Merck announced that it has successfully completed the acquisition of Acceleron Pharma
.
According to the agreement, Merck will acquire Acceleron for US$180 per share in cash, with a total equity value of approximately US$11.
5 billion
.
Acceleron is a clinical-stage biopharmaceutical company focusing on the research and development of anti-cancer drugs and rare drugs for rare diseases
.
On December 9, 2021, Thermo Fisher announced the completion of the acquisition of PPD for US$17.
4 billion
.
The transaction is expected to contribute $1.
50 to Thermo Fisher's adjusted earnings per share in 2022
.
PPD is a company that provides drug development services (CRO) for the biopharmaceutical and biotechnology industries, and has a history of 35 years
.
In fact, not only overseas pharmaceutical companies, but also domestic pharmaceutical companies' mergers and acquisitions continue to occur, but the transaction amount is relatively lower than that of overseas pharmaceutical companies
.
For example, Buchang Pharmaceuticals announced on October 14 this year that the company and its wholly-owned subsidiary Shenzhou Pharmaceuticals intends to acquire 100% of Beijing Chengrui's shares, with a total transaction price of 271 million yuan.
In September, Jiangzhong Pharmaceuticals announced that it intends to transfer equity.
And the acquisition of 51% equity of Hayes Pharmaceuticals by way of capital increase
.
According to incomplete statistics, as of the end of September 2021, there have been more than 100 mergers and acquisitions in China's pharmaceutical industry
.
Since the second half of the year, mergers and acquisitions have remained active, and a large number of companies including Buchang Pharmaceuticals and Yuanda Pharmaceuticals have also issued merger announcements
.
From the industry's perspective, in recent years, pharmaceutical companies have generally faced problems such as revenue growth pressure, patent expiration, and high cost of new drug development.
This has forced large pharmaceutical companies to continuously enrich their product pipelines and stabilize the situation through mergers and acquisitions
.
Some analysts predict that judging from current trends, large pharmaceutical companies may have a large number of mergers and acquisitions in 2022, and the total transaction is expected to exceed 1.
7 trillion US dollars
.
